drugset / Trial / NCT00640926

Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia

NCT00640926

Phase 2 Completed 158 enrolled Melinta Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether RX-1741, an oxazolidinone antibiotic, is safe and effective in the treatment of mild to moderate community acquired pneumonia (CAP).

Timeline

Start
2007-10
Primary completion
2009-03
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Radezolid Small molecule 300 mg Oral
Subject Radezolid Small molecule 450 mg Oral
Subject Radezolid Small molecule 900 mg Oral

Indications